Activity

Quimatryx develops new drugs against epigenetic targets. Our main goal is the development of new selective inhibitors of HDAC6, a epigenetic target related with several diseases, such as cancer, central nervous system diseases or autoimmune disorders.

Quimatryx's most advanced compound, QTX125, shows tumor regression and low toxicity in mantle cell lymphoma animal models. In addition, QTX125 is also effective against other cancers, such as pancreatic cancer, and central nervous system diseases, such as multiple sclerosis.